Avalyn Pharma Reports Q3 2026 Results, Ends Quarter With $386.6 Million

Avalyn Pharma reported a third-quarter 2026 net loss of $29.7 million, compared with $23.6 million a year earlier. Research and development expenses were $25.5 million, while general and administrative expenses were $7.6 million. The company ended the quarter with $386.6 million in cash, cash equiv…